Peggy Goodell

The Goodell Lab. Hematopoietic stem cells, epigenetics, DNA methylation. Chair, Dept of Mol Cell Biology at Baylor College of Medicine. Tweets my own.

[Peggy Goodell @Goodell_Lab]

@imartincorena Congrats! Great to see in final form. And what an issue- shared with @VamsiMootha with a fantastic somatic mosaicism story, tracking clones using mitochondrial DNA variants, and the inimitable @stephxie with human HSCs that exhibit memory of inflammatory exposure.

[Peggy Goodell @Goodell_Lab]

@VamsiMootha Congrats! Fantastic study! #mosaicism #hematology

[Peggy Goodell @Goodell_Lab]

Amazing paper showing somatic mutations and massive clonal selection for lymphocytes that drive autoimmune disease.

Autoimmune diseases are varied and individually relatively uncommon but as a group highly prevalent. These cause lots of morbidity to very many people, with huge personal, societal, and economic impact. If these findings are extended to other autoimmune conditions, they will have huge implications for treatment.

Lots in this paper - somatic evolution, new tech, old theories, mutations in your favorite genes... The thread is a great TL;DR for the paper.

Go deep and read the cited 2007 Goodnow paper (post#6) - amazingly detailed and prescient- from ~20 years ago!

[Inigo Martincorena @imartincorena]

Excited to share our latest work. Applying advanced single-molecule and single-cell DNA sequencing methods, we uncover an extraordinary landscape of somatic mutations in immune checkpoint genes in autoimmune lymphocytes. [1/n] https://t.co/8kQZ0NWl7X

[Peggy Goodell @Goodell_Lab]

@leonard_zon Congrats, Len!

[Peggy Goodell @Goodell_Lab]

@imartincorena Wow! Congrats @imartincorena and team! Amazing tour de force! Huge contribution to understanding autoimmunity.

[Peggy Goodell @Goodell_Lab]

@EinsteinMed @MontefioreNYC Congratulations Uli! Amazing!

[Peggy Goodell @Goodell_Lab]

@landau_lab @CD_AACR Congrats Dan! Awesome paper for the whole field.

[Peggy Goodell @Goodell_Lab]

Data on factors impacting time-to-acceptance could be crowd-sourced.

Major factors:
- time before first editor desk decision (varies a lot by editor and journal)
- review time (huge variation; also heavily influenced by the editors)
- editor decision time after reviews come in (can be longer than one would think)
– revision time (authors chasing very time-consuming experiments for the win; heavily influenced by (lack of) editor guidance, but also topic, model system...)
- second round (all same variables)
- possible appeal time (appeals are high at top journals and take even more time and can add to total time)

Journals track all this data. Authors should have it too.

Decent crowd-sourced data could be in ~real-time, and would help authors make informed decisions. I think many ppl would contribute data from their experience.

[Sasha Gusev @SashaGusevPosts]

Monthly median Received to Accepted time (days) at Nature Genetics

[Peggy Goodell @Goodell_Lab]

Great visit with an inspiring group of hematologists! 🙏

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful Visiting Professor Day today with Dr Peggy Goodell .@Goodell_Lab 🙏 for spending time with us at @UTMDAnderson Hematology Grand Rounds hosted by Dr @garciamanero & @doctorpemm | #leusm #endcancer | @sanamloghavi @DrKTakahashi @NitinJainMD @Daver_Leukemia |

[Peggy Goodell @Goodell_Lab]

Exciting new study demonstrating durable DNA methylation reprogramming (editing) in hematopoiesis!

[Vijay Sankaran @bloodgenes]

❓A one-time, durable, and even reversible way to prevent thrombosis? In this preprint, led by @lrbzldz, we show that epigenome editing of 🩸 #StemCells can durably reprogram platelet function: https://t.co/bioSZhRFuG

[Mick Milsom @MilsomMick]

First (to my knowledge) manuscript describing a correlation between number of infections and incidence of clonal hematopoiesis (CHIP). Really important from the perspective of highlighting a possible modifiable driver of CHIP during aging. @ISEHSociety https://t.co/DRtk6ScrJt

[Peggy Goodell @Goodell_Lab]

@RyanDhindsa @ABFbrain @CalebLareau @RNA_Life Congrats Ryan! All Star team!

[Peggy Goodell @Goodell_Lab]

@bloodgenes @NatureRevGenet @michaelpoeschla @BroadMPG @GRO_Broad @broadinstitute @DanaFarberNews @harvardmed @BostonChildrens @hhmi_science Nice comprehensive review! It will be useful for new lab members. And I love the vertical graphic!

[Peggy Goodell @Goodell_Lab]

An interesting question not addressed is the lifestyle differences of people with inactivating myostatin variants. You might guess that people with more muscle will excel in activities where those traits are valuable (e.g., athletics or certain jobs). Those activities might be self-reinforcing, further enhancing muscle growth and amplifying the apparent genetic effect over time. Lots more to learn, but a great investigation that will move the field forward. #aging #muscle #health

[Peggy Goodell @Goodell_Lab]

Remarkable new study showing that many individuals with genetic variants that disrupt the function of myostatin (a protein that normally inhibits muscle growth) have ⬆️muscle mass,⬇️ body fat, and ⬆️strength.

Increased muscle mass is clinically desirable for #healthyaging and for countering muscle loss in various contexts (including use of #GLP1 agonists). Below, MRI images of a subject with above-average muscle mass (left) and average muscle mass (right) from the study. Congrats @davidjglassMD and colleagues! Link ⬇️

[Peggy Goodell @Goodell_Lab]

It’s also a testament to the incredible societal value of these huge biobanks, the careful genotyping, thoughtful phenotyping, and mechanisms to make these available for analysis. THANK YOU to everyone who participates as a subject, to all the researchers who have worked so hard on these incredibly valuable resources, and to the funding bodies with foresight to invest in these. UKB and similar are truly transformative IMO.

[Peggy Goodell @Goodell_Lab]

@AbdelWahablab @natgenet @KellyLBolton @WashU @IrenaeusChan @PuZhang09980432 Congrats all! Glad to see this out!

[Peggy Goodell @Goodell_Lab]

Important work w real translational potential for cancer patients. Built on foundational science developed over years. Congrats to all!

[Abdel-Wahab Lab @AbdelWahablab]

Excited to announce a paper out today in @natgenet.nature.com identifying an approach to mitigate the risk of therapy-related myeloid malignancies in patients with cancer. Collaboration with @KellyLBolton @WashU and led by @IrenaeusChan & @PuZhang09980432

https://t.co/PkB6FViUCk